Ngo Alex, Fattakhov Nikolai, Toborek Michal
Department of Biochemistry and Molecular Biology, Miller School of Medicine, University of Miami, Miami, FL, USA.
Institute of Physiotherapy and Health Sciences, The Jerzy Kukuczka Academy of Physical Education, Katowice, Poland.
J Cereb Blood Flow Metab. 2024 Dec;44(12):1430-1440. doi: 10.1177/0271678X241281547. Epub 2024 Sep 9.
Strokes constitute over 50% of all neurological diseases, standing as the foremost cause of physical and mental disability. Currently, there are no widely accepted gold standard treatments for ischemic strokes beyond intravenous thrombolysis and mechanical thrombectomy applied during the acute therapeutic window. Therefore, the need for novel treatments targeting crucial signaling mediators involved in ischemic stroke is of utmost importance. The sigma-1 receptor (S1R), a molecular chaperone located at mitochondria-associated endoplasmic reticulum membranes (MAM), has exhibited neuroprotective effects when modulated by synthetic and endogenous agents across various cerebrovascular diseases. In this review, we describe the emerging therapeutic role of S1R agonists and antagonists in regulating blood-brain barrier (BBB) dysfunction, neuroinflammation, and neurocognitive impairment following ischemic stroke.
中风占所有神经系统疾病的50%以上，是导致身心残疾的首要原因。目前，除了在急性治疗窗口期间进行的静脉溶栓和机械取栓外，尚无广泛接受的缺血性中风金标准治疗方法。因此，开发针对缺血性中风关键信号介质的新型治疗方法至关重要。σ-1受体（S1R）是一种位于线粒体相关内质网膜（MAM）的分子伴侣，在各种脑血管疾病中，通过合成和内源性药物调节时，已显示出神经保护作用。在这篇综述中，我们描述了S1R激动剂和拮抗剂在调节缺血性中风后血脑屏障（BBB）功能障碍、神经炎症和神经认知障碍方面新出现的治疗作用。
